Abstract:Immune checkpoint blockades (ICB) have prompted a revolution in cancer treatment, but its low response rate and resistance remain a major problem. Clinical trials have reported the combination of ICB with chemotherapy can improve patient treatment outcome, but the synergy potential of most chemo drugs with ICBs are not systematically evaluated due to the limited insight of drug induced alterations in tumor microenvironment. Here, we reported a novel algorithm termed post-treatment-based synergy prediction for chemotherapy and ICB combination (POSEIDON). POSEIDON integrates one million drug-induced transcriptomic changes of T cell and cancer cells from the Library of Integrated Network-Based Cellular Signatures (LINCS) and ICB-induced single cell transcriptomic changes of 500K cells from tumor microenvironments across multiple cancer types. Using the gene expression signatures induced by chemotherapy and immunotherapy, POSEIDON utilized a reversal-orthogonal framework to predict the chemo compound that can potentially overcome ICB resistance and improve treatment beneficial. In an anti-PD1 treated melanoma patient cohort, POSEIDON identified a group of VEGFR inhibitors and HDAC inhibitors, including tivozanib and mocetinostat, showing the highest synergy potential with anti-PD1 therapy to reverse the anti-PD1 resistance through regulating T cell activities. In a triple negative breast cancer patient cohort who received the combination of anti-PDL1 and paclitaxel, POSEIDON also predicted several HDAC inhibitors (e.g., mocetinostat) and thymidylate synthase inhibitors (e.g., trifluridine) to synergize with the combination of anti-PDL1 plus paclitaxel and reverse the combination resistance through activating the immune response in tumor microenvironment. In addition to the synergy through tumor microenvironment, POSEIDON is also capable of predicting the synergy through tumor intrinsic mechanism. POSEIDON identified the genetic inhibition of EZH2 can potentially reverse anti-PD1 resistance via upregulation of tumor antigen presentation and interferon signaling. The synergy between EZH2 inhibitor and anti-PD1 was further validated in vivo by treating the anti-PD1 resistant 4T1.2 mouse model with FDA approved EZH2 inhibitor tazemetostat and PD1 antibody. Our data showed that, while tazemetostat or anti-PD1 alone failed to inhibit tumor growth, the combination of tazemetostat and anti-PD1 can significantly reduce the tumor size and increase overall survival. Collectively, our study demonstrated that POSEIDON can provide reliable prediction of chemo-immunotherapy synergism by integrating the post-treatment transcriptomic profiles from patient tumor microenvironment and cell lines. We envision that the systematic identification of chemo-immunotherapy synergism will help cancer patients to cope with immunotherapy resistance in the short future. Citation Format: Yue Wang, Yifei Wang, Xiaofei Wang, Zehua Wang, Min Zhang, Da Yang. Systematic identification of the chemo-immunotherapy synergism to overcome immunotherapy resistance in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5594.

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy

A Novel Strategy Conjugating PD-L1 Polypeptide With Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer

Oral delivery of anti-PD-L1 antibody for cancer immunotherapy against orthotopic colorectal tumors

Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Transient and Local Expression of Chemokine and Immune Checkpoint Traps to Treat Pancreatic Cancer.

Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy

A Synergistic Chemoimmunotherapy System Leveraging PD-L1 Blocking and Bioorthogonal Prodrug Activation

Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses

Immunogenic Bifunctional Nanoparticle Suppresses Programmed Cell Death-Ligand 1 in Cancer and Dendritic Cells to Enhance Adaptive Immunity and Chemo-Immunotherapy

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses

Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function

Nano-Liposome Co-Loaded with C-X-C Chemokine Ligand 12/CXCR4 Pathway Inhibitor Synergistically Increases the Immune Efficacy of Anti-PD-L1 and Increase Anti-Tumor Activity of Effector T Cells

Abstract 5594: Systematic identification of the chemo-immunotherapy synergism to overcome immunotherapy resistance in cancer

In situ vaccination and gene-mediated PD-L1 blockade for enhanced tumor immunotherapy

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy